Document is current

Article History

Received: 21 December 2020

Accepted: 22 January 2021

First Online: 2 February 2021

Compliance with ethical standards

:

: DISCLOSURE OUTSIDE THE SUBMITTED WORK: LR reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Roche.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study. The study protocol was reviewed and approved by the local Area Vasta Emilia Nord Ethics committee (number 292; data of approve 10/10/2017) and was conformed to the ethical guidelines of the 1975 Declaration of Helsinki. All patients signed the informed consent.